000141595 001__ 141595
000141595 005__ 20230915100912.0
000141595 0247_ $$2doi$$a10.1055/a-0972-1552
000141595 0247_ $$2pmid$$apmid:31639883
000141595 0247_ $$2ISSN$$a0023-2165
000141595 0247_ $$2ISSN$$a0344-6360
000141595 0247_ $$2ISSN$$a0344-6387
000141595 0247_ $$2ISSN$$a1439-3999
000141595 0247_ $$2altmetric$$aaltmetric:73442589
000141595 037__ $$aDZNE-2020-07919
000141595 041__ $$ager
000141595 1001_ $$0P:(DE-HGF)0$$aPriglinger, Claudia$$b0$$eCorresponding author
000141595 245__ $$a[Leber's Hereditary Optic Neuropathy].
000141595 260__ $$aStuttgart$$bThieme78968$$c2019
000141595 264_1 $$2Crossref$$3online$$bGeorg Thieme Verlag KG$$c2019-10-22
000141595 264_1 $$2Crossref$$3print$$bGeorg Thieme Verlag KG$$c2019-11-01
000141595 3367_ $$2DRIVER$$aarticle
000141595 3367_ $$2DataCite$$aOutput Types/Journal article
000141595 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1587469079_3654
000141595 3367_ $$2BibTeX$$aARTICLE
000141595 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141595 3367_ $$00$$2EndNote$$aJournal Article
000141595 520__ $$aLeber's hereditary optic neuropathy (LHON) typically affects young adults with a higher prevalence in men, but can ultimately occur at any age and also in women. LHON is caused by point mutations in the mitochondrial DNA, which lead to a defect in complex I of the mitochondrial respiratory chain. This in turn causes dysfunction and later degeneration of retinal ganglion cells, followed by ascending optic atrophy. Classically, LHON presents as a subacute unilateral loss of visual acuity, dyschromatopsia in the red-green axis and a central or centrocecal scotoma. The partner eye usually develops similar symptoms within 3 - 6 months of onset of the disease. In 25% of cases, however, the disease begins bilaterally. In the natural course of the disease, the majority of patients remain with a visual acuity less than 0.1, even though a small proportion may experience a spontaneous improvement in visual acuity. In 2015, the ubiquinone analogue Idebenone was approved by the European Medicines Agency for the treatment of LHON. The decisive factors for therapeutic success are an early start and an appropriate treatment duration. It should also be noted that a proportion of patients may experience a delayed response to therapy. However, a complete recovery of visual acuity is rare even under therapy. Since patients affected by LHON are mostly young adults of working age, who go largely blind more or less acutely, immediate support with magnifying vision aids and advice on social and vocational rehabilitation is essential. Alternative therapeutic approaches such as gene therapy, neuroprotection or stem cell-based aspects are currently the subject of clinical studies and offer hope for further perspectives for those affected. Although with Idebenone a causal therapy has already been approved for LHON, many questions regarding the pathogenesis of the disease have not yet been completely clarified. This particularly concerns gender prevalence and possible additional triggers or protective factors. In this overview, the clinical course of LHON, diagnostics and current therapy recommendations as well as the special features and current explanatory approaches to incomplete penetrance and symptoms of LHON are explained.
000141595 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000141595 588__ $$aDataset connected to CrossRef, PubMed,
000141595 650_7 $$2NLM Chemicals$$aDNA, Mitochondrial
000141595 650_2 $$2MeSH$$aDNA, Mitochondrial
000141595 650_2 $$2MeSH$$aFemale
000141595 650_2 $$2MeSH$$aGenetic Therapy
000141595 650_2 $$2MeSH$$aHumans
000141595 650_2 $$2MeSH$$aMale
000141595 650_2 $$2MeSH$$aOptic Atrophy, Hereditary, Leber: genetics
000141595 650_2 $$2MeSH$$aOptic Atrophy, Hereditary, Leber: therapy
000141595 650_2 $$2MeSH$$aRetinal Ganglion Cells
000141595 650_2 $$2MeSH$$aVisual Acuity
000141595 650_2 $$2MeSH$$aYoung Adult
000141595 7001_ $$0P:(DE-2719)2810704$$aKlopstock, Thomas$$b1$$udzne
000141595 7001_ $$aRudolph, Günter$$b2
000141595 7001_ $$aPriglinger, Siegfried Georg$$b3
000141595 77318 $$2Crossref$$3journal-article$$a10.1055/a-0972-1552$$b : Georg Thieme Verlag KG, 2019-10-22$$n11$$p1271-1282$$tKlinische Monatsblätter für Augenheilkunde$$v236$$x0023-2165$$y2019
000141595 773__ $$0PERI:(DE-600)2752067-5$$a10.1055/a-0972-1552$$gVol. 236, no. 11, p. 1271 - 1282$$n11$$p1271-1282$$q236:11<1271 - 1282$$tKlinische Monatsblätter für Augenheilkunde$$v236$$x0023-2165$$y2019
000141595 909CO $$ooai:pub.dzne.de:141595$$pVDB
000141595 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810704$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000141595 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000141595 9141_ $$y2019
000141595 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bKLIN MONATSBL AUGENH : 2019$$d2021-01-29
000141595 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-29
000141595 9201_ $$0I:(DE-2719)1111016$$kClinical Dementia Research München$$lClinical Dementia Research München$$x0
000141595 980__ $$ajournal
000141595 980__ $$aVDB
000141595 980__ $$aI:(DE-2719)1111016
000141595 980__ $$aUNRESTRICTED